Ciprofloxacin was tested for its inhibitory or stimulatory effects on concanavalin A-and phytohemagglutininstimulated proliferation (measured by [3H]thymidine uptake) of human peripheral blood mononuclear cells and murine splenocytes, Ciprofloxacin did not diminish or enhance mononuclear cell proliferation at concentrations of 5 to 125 ,ug/ml. Further, the proliferative response of splenocytes of mice previously treated with ciprofloxacin (40 mg/kg, twice daily for 5 days) was essentially similar to Tbat of untreatesl controls.
The effect of several classes of antibiotics on the functional capacity of human peripheral blood mononuclear cells (MNCs) to proliferate in response to mitogens and antigens has been studied 'by sevqral investigators (1, 4, (7) (8) (9) 11) , Thus certain tetracyclines, such as doxycycline and minocycline, and cephalqspqrins, such as cephalothin, cephalexin, cephradine, pofamnindole, cephapirin, 'cefoxitin, moxalactam, and cefuroxime, have been shown to produce a dose-dependent suppression of MNC proliferation induced by concanavalin A (~onA) and phytohemagglutinin (PHA) (4, 8, 9, 11) . However, penicillins, including carbenicillin and benzylpenicillin, do not inhibit the proliferative response of MNCs (1). These rep'orts indicate that some antibiotics adversely affect the metabolic processes of MNCs and consequently may interfere with their function.
In this study, we investigated the possible inhibitory and stimulatory effects of ciprofloxacin, a new quinolone derivative, on mitogen-stimulated proliferation of human MNCs and murine splenocytes.
MNCs were isolated from heparinized peripheral blood obtained from healthy donors by density gradient centrifugation over Ficoll-Hypaque (Pharmacia Fine Chemicals, Piscataway, N.J.) (3) . The effect of ciprofloxacin was tested separately on MNCs derived from four different donors.
Swiss Webster mice (8 to 12 weeks old; Simonsen Laboratories, Gilroy, Calif.) were used for studies on the in vivo effect of ciprofloxacin. Groups of five mice each were injected intraperitioneally twice daily for 5 days with ciprofloxacin (40 mg/kg) or phosphate-buffered saline (for controls). The mice were killed 1 to 2 days after treatment, their spleens were removed, a single cell suspension of mouse spleen cells was prepared (5), and their proliferative response to ConA was assessed. These experiments were repeated twice. The proliferation of MNCs and splenocytes was measured by [3H]thymidine uptake (6) The addition of ciprofloxacin to MNC cultures did not interfere with cell proliferation (Table 1) . At a concentration of 125 pLg/ml, ciprofloxacin had no effect on the ConAinduced MNC proliferative response. Prior treatment of mice with ciprofloxacin did not appreciably alter the ability of their lymphocytes to respond to ConA (thymidine incorporation in splenocytes of control and ciprofloxacin-treated mice was 144,562 ± 15,226 and 133,682 ± 12,682 cpm, respectively). At the time the spleens were removed for these experiments, there were no detectable antibiotic levels in the serum, as determined by a bioassay (2) with Klebsiella pneumoniae ATCC 10031. The mean peak level of antibiotic in the serum of mice treated with a single intraperitoneal injection of 40 mg of ciprofloxacin per kg was 7 ,ug/ml. When murine splenocytes were stimulated with optimal concentrations of ConA in the presence of 7 ,ug of ciprofloxacin per ml, there was no effect on cell proliferation, as assessed by
[3H]thymidine uptake.
At present, very little is known about the effects of ciprofloxacin on mammalian cellular metabolism, but quinolone derivatives appear to be capable of inhibiting eucaryotic DNA polymerases alpha and beta and deoxynucleotidyltransferase in cell-free systems (10) . The results presented here demonstrate that in an intact cell system, ciprofloxacin appears to be inactive in the suppression of normal human MNC and murine splenocyte proliferation. The inability of ciprofloxacin to modulate the proliferative responses may be a reflection of the failure of the drug to 
